Biopharmaceutical Companies - Important Piece to Help Solve the Alzheimer's Puzzle

Biopharmaceutical Companies - Important Piece to Help Solve the Alzheimer's Puzzle

02.07.12 | By

The White House today unveiled new efforts to help fight Alzheimer' disease, including providing additional funding for research, caregiver support and provider education.

We share the same goal as the Administration - we want to put an end to the devastating toll this disease has on patients, their caregivers and even the U.S. health care system. If you didn't already know, future projections show that one American will develop the disease every 33 seconds in 2050, costing the U.S. health care system $1.1 trillion.

On the Catalyst, we have written extensively about biopharmaceutical companies efforts to find a treatment for Alzheimer's. With nearly 100 new medicines in development to help treat patients with Alzheimer's and related dementias, hope is certainly on the horizon.

Finding a novel Alzheimer's treatment is not an easy task and public-private partnerships in this space can help move forward the scientific understanding of this complex disease. One remarkable example of industry collaboration with federal research institutions is the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large five year research project to define the rate of progress of Alzheimer's disease, develop improved methods for clinical trials in this area, and to provide a large database which may improve development of innovative treatments.

Importantly, innovative biopharmaceutical companies are an important piece to solving the complex Alzheimer's puzzle and a critical part of the solution to what is becoming a health and economic crisis. But we recognize that it is imperative that we continue to work together - industry, academia and federal research institutions - to build on existing knowledge and research that can help move progress forward to combat this devastating disease.

Follow Jen on Twitter @JenAtPhRMA

More On PhRMA — powered by PhRMApedia


Cost in Context